5 Major Research Reports From Studies Using Daxor's Blood Volume Analyzer Presented at the 39th Annual Society of Critical Care Medicine Conference. Part I: Studies on Leaky Capillary Syndrome

NEW YORK, NY--(Marketwire - January 22, 2010) - Daxor Corporation (NYSE Amex: DXR), a medical instrumentation and biotechnology company, today announced that five major research reports derived from studies using the Daxor Blood Volume Analyzer (BVA-100) were presented at the annual Society of Critical Care Medicine (SCCM) conference in Miami, FL. The BVA-100 enables measurement of whole blood volume, including plasma volume and red blood cell volume. It also permits measurement of the rate of transudation of albumin across the capillaries. Albumin is an essential carrier protein, which helps to maintain blood pressure. The Principal Investigators for these studies were Mihae Yu, MD, and Danny Takanishi Jr., MD, from the University of Hawaii, The Queen's Medical Center. Abstracts which describe their findings were published in the December 2009 Supplement (Volume 37, Number 12) of the Critical Care Medicine journal. Two of these presentations are now available on Daxor's website at www.daxor.com/sccm2010.asp.

Two of these studies focused on the rate of loss of albumin from the intravascular system, which is very slow in normal individuals. In patients with sepsis, however, loss of vascular integrity results in loss of fluids and proteins and a corresponding decrease in blood volume. The medical term for this is "leaky capillary syndrome," and it may result in collapse of blood pressure and sudden death. With repair of the vascular injury, these intravascular fluid losses are minimized and patients can recover. One of the studies, entitled "Activated Protein C (APC) and Corticosteroids Decrease the Rate of Albumin Transudation in Septic Shock" examined whether APC and corticosteroids may affect capillary permeability in 75 patients with severe sepsis/septic shock. The results show that either corticosteroids alone or APC and corticosteroids together significantly decreased elevated transudation rates. A lower mortality rate was observed in the group receiving corticosteroids alone relative to the APC and corticosteroid combination group. Although it has long been assumed that the corticosteroid hydrocortisone stabilizes capillary transudation in septic shock, this study is the first involving direct blood volume measurement and albumin capillary loss to actually demonstrate this.

Another study, entitled "Elevated Transcapillary Albumin Escape: A Marker of Increased Mortality" directly examined the relationship between albumin leak rate and mortality in 100 patients requiring radial or pulmonary artery catheter for acute resuscitation of severe sepsis, septic shock, cardiogenic shock and/or Acute Respiratory Distress Syndrome. Patients with a normal albumin leak rate 5-7 days after resuscitation showed markedly lower mortality (7.8%) than patients with elevated albumin leak rate (27.9%). This study confirms that transcapillary albumin escape is, in fact, a marker for increased mortality. This opens up the possibility of using this measurement to evaluate the efficacy of different therapies in reducing capillary albumin leak.

The following investigators were involved in these studies: Mihae Yu, MD, Danny Takanishi, Jr., MD, David Inouye, MD, Michael Hayashi, MD, Shirley Domingo, MD, Susan Steinemann, MD, Fedor Lurie, MD, Mona Ghows, MD, and Sharon Moran, MD. Further details can be viewed on Daxor's website.

Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website www.Daxor.com.

Contact Information: Contact Information: Dr. Sandra Gilbert Clinical Research Coordinator 212-330-8532 sgilbert@daxor.com Stephen Feldschuh Chief Operating Officer 212-330-8500 stephen@daxor.com Diane Meegan Investor Relations 212-330-8512 dmeegan@daxor.com